Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

437

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2027

Conditions
Mature B-Cell Malignancies
Interventions
DRUG

Sonrotoclax

Film-coated tablets administered once daily at a dose as specified in the treatment arm

DRUG

Zanubrutinib

320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)

DRUG

Obinutuzumab

Given as an intravenous infusion administered per label.

Trial Locations (44)

1023

Auckland City Hospital, Auckland

2139

Concord Repatriation General Hospital, Concord

2800

Orange Health Service (Central West Cancer Care Centre), Orange

3000

Peter Maccallum Cancer Centre, Melbourne

3004

The Alfred Hospital, Melbourne

3065

St Vincents Hospital Melbourne, Fitzroy

3128

Box Hill Hospital, Box Hill

3168

Monash Health, Clayton

4217

Pindara Private Hospital, Benowa

4224

John Flynn Private Hospital, Tugun

5000

Royal Adelaide Hospital, Adelaide

5042

Flinders Medical Centre, Bedford PK

6009

Linear Clinical Research, Nedlands

6021

Wellington Regional Hospital (Ccdhb), Wellington

6132

Ospedale Santa Maria Della Misericordia, Perugia

8036

Hospital Clinic de Barcelona, Barcelona

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center Mskcc, New York

15232

Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh

20132

Ospedale San Raffaele, Milan

20162

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan

28040

Start Madrid Fundacion Jimenez Diaz, Madrid

31008

Clinica Universidad de Navarra Pamplona, Pamplona

37007

Hospital Universitario de Salamanca, Salamanca

37134

Centroricerche Cliniche Di Verona Srl, Verona

39008

Hospital Universitario Marques de Valdecilla, Santander

43210

The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus

48121

Azienda Unita Sanitaria Locale Di Ravenna, Ravenna

55905

Mayo Clinic Rochester, Rochester

60611

Northwestern University, Chicago

66160

University of Kansas Medical Center Research Institute, Kansas City

68198

University of Nebraska Medical Center, Omaha

77030

Md Anderson Cancer Center, Houston

90095

UCLA Hematologyoncology, Los Angeles

98109

Fred Hutchinson Cancer Research Center, Seattle

02114

Massachusetts General Hospital, Boston

07601

John Theurer Cancer Center Hackensack University Medical Center, Hackensack

01307

Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden, Dresden

00168

Fondazione Policlinico Universitario Agostino Gemelli, Roma

0622

North Shore Hospital, Takapuna

08025

Hospital de La Santa Creu I Sant Pau, Barcelona

08035

Vall D Hebron Institute of Oncology Vhio, Barcelona

08907

Ico H Duran I Reynals, Barcelona

LS9 7TF

The Leeds Teaching Hospitals Nhs Trust, Leeds

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT04277637 - Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies | Biotech Hunter | Biotech Hunter